PD-1+ CD4+ T-cell was a negative predictor for immunotherapy availability in advanced NSCLC patients, while PD-1+CD8+ T-cell was a positive predictor (85, 103–105, 108). This evidence concerns the gene CD8A and non-small cell lung carcinoma.